PreciseDx

Executive Summary

PreciseDx is an AI-driven precision pathology company addressing a critical unmet need in oncology: the subjectivity of current tumor grading standards, which often results in intermediate-risk classifications and prolonged wait times for gene expression tests. By applying machine learning to histopathology images, PreciseDx aims to provide objective, rapid, and accurate risk stratification, enabling timely treatment decisions. Founded in 2017 and headquartered in New York, the company operates in the AI/ML space without disclosed funding or valuation. If validated, their technology could reduce diagnostic delays from weeks to minutes and improve patient outcomes by personalizing care plans. While early-stage and private, PreciseDx's focus on a clear clinical pain point positions it for potential partnerships with pathology labs or pharmaceutical companies.

Upcoming Catalysts (preview)

• Q4 2026Clinical validation study publication for AI grading algorithm65% success
• Q2 2027Strategic partnership with a major pathology lab or health system50% success
• Q3 2027FDA breakthrough device designation or clearance40% success